Antibody Drugs Market: Latest Research Report to Share Market Insights and Dynamics of Profiled Key Players
Seattle, WA -- (SBWIRE) -- 11/15/2019 -- Antibody drugs are created through the use of modern scientific techniques such as genetic engineering and recombinant deoxyribonucleic acid (DNA) technology. They are produced by living cells and organisms such as Escherichia coli (E. coli), yeast, mammalian cells, etc. These protein drugs have gained in significance due to the increase in the number of chronic diseases such as asthma, multiple sclerosis and arthritis, and fatal diseases such as cancer and cardiovascular diseases.
Get more info about "Global Antibody Drugs Market Report" by requesting Sample Copy HERE: https://www.worldwidemarketreports.com/sample/25074
Market Growth Factors:
The antibody drug industry has grown globally due to its pivotal role in the treatment of life-threatening diseases. This report analyzes and assesses the therapeutic applications of antibodies such as mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agents, such as antibody drug conjugates.
Genetic engineering technology has made it possible to produce these protein molecules with modified features. Owing to its high specificity and low immunogenicity, protein therapeutics is widely used to treat various life-threatening diseases such as cancer, diabetes and multiple sclerosis. Increasing R&D, increasingly sedentary lifestyles, increasing incidence of various diseases and the growing population of baby-boomers are the driving forces for the monoclonal antibody market.
Leading manufacturers are F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Biogen Inc., Amgen Inc., Merck KGaA, Seattle Genetics Inc. and AbbVie Inc. More and more novel antibody drugs are being investigated and developed due to advances in technology.
Market segment by Type, the product can be split into
Market segment by Application, split into
Central Nervous System (CNS) Disorders
Humanized monoclonal antibodies (mAbs) are the largest segment in terms of revenue, followed by other mAb categories such as human, chimeric and murine. The use of mAbs in therapeutics such as oncology, autoimmune and inflammatory diseases is expected to increase during the forecast period although this market is likely to face competition from the entry of follow-on-biologics and biosimilars.
Want to make an inquiry before purchasing this report and also want a discount? Click HERE: https://www.worldwidemarketreports.com/quiry/25074
THANKS FOR SPENDING YOUR VALUABLE TIME ON THIS VALUABLE PIECE OF INFORMATION!